Adimab Antibody Discovery Platform
Provider 
Founded 2007
Sells To Enterprise
Pricing Model Licensing, Recurring
Ownership Public

Adimab's antibody discovery platform uses an engineered yeast system and fully human libraries to isolate therapeutic antibodies.
Adimab operates a yeast-based antibody discovery platform that combines engineered Saccharomyces cerevisiae display with fully human synthetic antibody libraries and iterative MACS/FACS enrichment, supported by AI/ML-guided design. The workflow is built to surface high-affinity, developable fully human antibodies against chosen therapeutic targets.
The platform is offered to partners across the biopharmaceutical industry for early antibody discovery and optimization. Its combination of immune-library diversity and yeast display positions it as an alternative to animal-based and purely computational antibody generation methods.
AbCellera Biologics

Antibody Discovery Platform
abcellera.com
Prellis Biologics

EXIS
prellisbio.com
OmniAb

OmniAb Antibody Discovery Platform
omniab.com
| Attribute | Adimab Antibody Discovery Platform | Antibody Discovery Platform | EXIS | OmniAb Antibody Discovery Platform | |
|---|---|---|---|---|---|
| Provider | |||||
| Founded | 2007 | 2012 | 2016 | 2021 | |
| Sells To | Enterprise | Enterprise, Government | Enterprise | Enterprise | |
| Pricing Model | Licensing, Recurring | Recurring, Software | Recurring, Software | Recurring | |
| Ownership | Public | Public | Private equity-backed, Venture-backed | Private |
Provider 
Founded 2007
Sells To Enterprise
Pricing Model Licensing, Recurring
Ownership Public
Provider 
Founded 2012
Sells To Enterprise, Government
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2016
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private equity-backed, Venture-backed
Provider 
Founded 2021
Sells To Enterprise
Pricing Model Recurring
Ownership Private